NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

CompletedN/A

Sponsor: St. Jude Children's Research Hospital

Conditions: Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia

Interventions: Rasburicase

Countries: United States

This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* A diagnosis of hematologic malignancy.
* Existing hyperuricemia or high risk of developing hyperuricemia of malignancy.
* The treating clinician plans to treat the patient with rasburicase. A patient is only eligible for RASALL if the clinician has already decided to use rasburicase. Rasburicase should not be given in order to make a patient eligible for this non-therapeutic observational study.
* No prior exposure to rasburicase or other urate oxidase.
* A history of asthma or significant allergy.

Exclusion Criteria

* Wheezing or an active hypersensitivity reaction at entry.
* Hypersensitivity to Aspergillus proteins.

Locations (11)

Palo Alto, California, United States
San Diego, California, United States
Indianapolis, Indiana, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
New York, New York, United States
Providence, Rhode Island, United States
Memphis, Tennessee, United States
Fort Worth, Texas, United States
Houston, Texas, United States
Milwaukee, Wisconsin, United States